

Clinical trials of once daily nadroparin

TrialResults-center www.trialresultscenter.org

1 venous thrombosis

Trial	Treatments	Patients	Trials design and methods
once daily nadroparin vs twice daily nadroparin			
Charbonnier , 1998 n=316/335 follow-up:	Once daily nadroparin 20,500 (AXa IU/ml)continued for at least 5 days versus twice daily nadroparin 10,250 (AXa IU/ml)continued for at least 5 days	patients with acute symptomatic proximal DVT in popliteal vein or above documented by venography	Parallel groups double blind Europe

More details and results :

- antithrombotics for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q101>
- LMWH for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q203>
- heparin (UFH or LMWH) for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q204>

References

Charbonnier, 1998:

Charbonnier BA, Fiessinger JN, Banga JD, Wenzel E, d'Azemar P, Sagnard L Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group. Thromb Haemost 1998;79:897-901 [[9609216](#)]

Entry terms: nadroparin, Nadroparine, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216, LMF CY-216, LMF CY 216, LMF CY216,